What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the Phase 3 trials (BaxHTN and Bax24) shows comparable efficacy to existing options, with significant reductions in seated SBP and ambulatory BP. However, there is no active comparator data against guideline-preferred therapies like spironolactone, which limits the ability to claim superiority. The absence of hard clinical outcomes further supports a B++ rating.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness analyses or ICER data are available for baxdrostat, as NICE’s appraisal is still in development and no public economic models have been released. This lack of economic evaluation leads to a C rating.
Is there quality-of-life evidence payers weigh? — Quality of life
There is no evidence of HRQoL data or validated instruments used in the trials. The absence of any patient-reported outcomes or utility values indicates a critical gap in understanding the treatment’s impact on quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile from the BaxHTN trial indicates that adverse events were mostly mild, with serious adverse events occurring at low rates. The reported safety signals are consistent with the expected pharmacological effects, supporting a strong safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The trials primarily used placebo as a comparator, which is acceptable for assessing efficacy but does not provide direct evidence against standard of care treatments like spironolactone. This limits the robustness of the comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
While the trial population is described, there are notable representativeness concerns, particularly regarding the under-representation of women and Black participants. This limits the generalizability of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Baxdrostat can be integrated into existing treatment pathways as an add-on therapy, aligning with current guidelines for resistant hypertension. However, it requires monitoring for electrolyte levels, which may necessitate some adjustments.
Are the wider system costs understood? — Resource Use and Cost Implications
There is no available data on the resource implications or budget impact of baxdrostat, and no analyses quantifying implementation costs have been identified. This lack of information leads to a C rating.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is derived from well-designed Phase 3 trials with rigorous methodologies. However, the absence of long-term outcomes and active comparator data introduces some limitations, justifying an A rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term outcomes and the translation of BP lowering into clinical benefits, the evidence presented is relatively stable. However, the lack of equity and access data introduces some concerns.
